Fed Cuts Rates by 25bps as Expected Amid Growing Divergence; DRC Sets New Cobalt Export Rules

Stock News12-11

**Key Highlights** The Federal Reserve delivered its third consecutive rate cut this year, lowering the federal funds rate by 25 basis points to 3.5%-3.75%. However, policymakers maintained their projection for only one rate cut in 2026, highlighting deepening divisions over future policy. The FOMC voted 9-3 for the cut and adjusted its statement to reflect greater uncertainty about the timing of further easing. Separately, the Fed announced a $40 billion monthly Treasury bill purchase program starting December 12 to replenish bank reserves depleted during quantitative tightening.

**Market Overview** Global silver prices hit record highs, with spot silver rising 1.88% to $61.81/oz and COMEX silver futures up 2.24% at $62.20/oz. U.S. stocks gained, led by tech and infrastructure shares: GE Vernova surged 15% to a record high, while Caterpillar rose 3%. Hong Kong ADRs climbed 0.55%, tracking the HSI.

**Sector Focus** - **Cobalt**: Glencore declined to comment on reports it became the first company to export cobalt under the DRC’s new quota system, which mandates 10% royalty prepayments. CMOC Group’s Tenke Fungurume mine is also preparing shipments. - **Batteries**: Samsung SDI secured a $13.6B LFP battery order for U.S. energy storage systems, marking Korean firms’ pivot from NMC to LFP technology. - **AI Hardware**: Quark AI glasses face 45-day delivery delays due to overwhelming demand, prompting emergency production ramp-up.

**Corporate Updates** - **Hainan Airport** finalized procedures to acquire Meilan Airport’s controlling stake for RMB2.34B. - **Lens Technology** (06613) agreed to acquire PMG International, expanding into AI computing infrastructure. - **Sunny Optical** (02382) reported November auto lens shipments up 69.4% YoY. - **CSPC Pharma** (01093) and **Shanghai Pharma** (02607) received U.S. and Chinese trial approvals for new drugs, respectively. - **Ascletis Pharma** (01672) had its acne treatment NDA accepted by China’s NMPA.

**Stock Spotlight: SINOTRUK (03808)** China’s heavy truck sales jumped 46% YoY in November, with SINOTRUK on track to meet its 300K annual target. The company plans disciplined CAPEX (≤RMB2B/year) for overseas expansion while maintaining ≥55% dividend payout ratios. BofA raised 2025-27 EPS estimates by 4-10%, citing higher-margin international sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment